论文部分内容阅读
在芝加哥召开的美国肝病会议上,Trepo 详细介绍了用特异性血清学试验检测非甲非乙型肝炎病毒抗原和抗体的经验。根据 Trepo 的研究,许多人已表明这样的信念:以实用的方法对库存血进行非甲非乙型肝炎的筛选,可能不久就会成为现实,这样就可以控制占输血后肝炎大约90%的感染。1978年10月,Ryoichi Shirachi 等曾报道了用免疫扩散法成功地检出一种非甲非乙型肝炎抗原。Trepo 和 Alfred Prince 等进一步应用这些方法,以受感染动物和病人的抗体通过沉淀素反应检出了这种非甲非乙型肝炎病毒的两种成分—核心抗原和 e 抗原(e 抗原是病毒核心的非颗粒成分)。免疫扩散法对非甲非乙型肝炎是特异的,但不够敏感,血清学检查只能检出40～60%的病例。
At the American Liver Disease Conference in Chicago, Trepo detailed his experience with specific serological tests for detecting non-A, non-B hepatitis antigens and antibodies. According to Trepo’s research, many people have shown the conviction that a practical screening of non-A, non-B hepatitis B virus in stocked blood may soon become a reality, and that about 90% of infections that account for post-transfusion hepatitis can be controlled . In October 1978, Ryoichi Shirachi et al. Reported successful detection of a non-A, non-B hepatitis antigen by immunodiffusion. These methods were further used by Trepo and Alfred Prince et al. To detect the two components of this non-A, non-B hepatitis virus, the core antigen and the e antigen (the e antigen is the core of the virus) by the amylin reaction using antibodies from infected animals and patients Of non-particulate ingredients). Immunoprophylaxis is specific to non-A, but not sensitive, serological tests only detect 40-60% of cases.